Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v6-EN Version v4-EN
Language English English
Date Updated 2019-06-07 2019-06-06
Drug Identification Number 02378434 02378434
Brand name LOVENOX LOVENOX
Common or Proper name Lovenox Lovenox
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients ENOXAPARIN SODIUM ENOXAPARIN SODIUM
Strength(s) 80MG 80MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS
Packaging size 10 10
ATC code B01AB B01AB
ATC description ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS
Reason for shortage Delay in shipping of the drug. Delay in shipping of the drug.
Anticipated start date 2019-05-29 2019-05-29
Actual start date
Estimated end date 2019-06-15 2019-06-15
Actual end date 2019-06-06 2019-06-06
Shortage status Resolved Actual shortage
Company comments The anticipated availability dates represent estimated availabilities at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy. The anticipated availability dates represent estimated availabilities at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Patients should validate the availability of the product with their respective pharmacy.
Health Canada comments